Following encouraging initial results, which will be published shortly, the Institut Pasteur and SpikImm announce the development of the antibody SPKM001.
Paris, September 9, 2021
SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the Spike protein of the original SARS-CoV-2 strain and its variants.
Initial preclinical results tend to show that this new therapeutic tool is effective in vitro and in vivo. Clinical trials should be conducted to evaluate its efficacy in humans.